CHOSA Stock Overview
Develops oncology drugs for the treatment of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Chosa Oncology AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.53 |
| 52 Week High | SEK 2.25 |
| 52 Week Low | SEK 0.30 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | 51.43% |
| 1 Year Change | -59.23% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -62.30% |
Recent News & Updates
Recent updates
Shareholder Returns
| CHOSA | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 0% | -3.9% | 2.6% |
| 1Y | -59.2% | 11.5% | 13.5% |
Return vs Industry: CHOSA underperformed the Swedish Biotechs industry which returned -2.4% over the past year.
Return vs Market: CHOSA underperformed the Swedish Market which returned 9.4% over the past year.
Price Volatility
| CHOSA volatility | |
|---|---|
| CHOSA Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 8.6% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 12.0% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: CHOSA's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine CHOSA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2022 | n/a | Peter Jensen | www.chosaoncology.com |
Chosa Oncology AB develops oncology drugs for the treatment of cancer. The company was formerly known as Chosa ApS. Chosa Oncology AB incorporated in 2022 and is based in Lund, Sweden.
Chosa Oncology AB Fundamentals Summary
| CHOSA fundamental statistics | |
|---|---|
| Market cap | SEK 34.38m |
| Earnings (TTM) | -SEK 23.94m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.4x
P/E RatioIs CHOSA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CHOSA income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 23.94m |
| Earnings | -SEK 23.94m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 10, 2024
| Earnings per share (EPS) | -0.37 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CHOSA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/04/30 13:16 |
| End of Day Share Price | 2024/02/01 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Chosa Oncology AB is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.